View More Recent Stories

Jan 13, 2021 08:00AM UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
Jan 6, 2021 08:00AM UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Dec 4, 2020 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 3, 2020 08:00AM UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology
Nov 17, 2020 08:05AM UroGen Pharma (URGN) Reports Final Topline Results from OPTIMA II Phase 2b Final Results for UGN-102; 'Complete and Durable Responses Observed'
Nov 17, 2020 08:00AM Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
Nov 11, 2020 08:00AM Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
Nov 10, 2020 08:00AM UroGen Pharma Announces November 2020 Conference Schedule
Nov 9, 2020 08:00AM UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
Nov 2, 2020 08:00AM UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020
Oct 5, 2020 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 10, 2020 08:00AM UroGen Pharma Announces September 2020 Conference Schedule
Sep 9, 2020 08:00AM UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
Sep 4, 2020 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 27, 2020 08:04AM UroGen Pharma (URGN) Phase 2 Trial of RTGel Hydrogel Formulation in Combination with BOTOX Intravesical Instillation for Overactive Bladder and Urinary Incontinence Did Not Meet Primary Endpoint
Aug 27, 2020 08:00AM UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary In
Aug 10, 2020 08:00AM UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
Aug 3, 2020 08:00AM UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
Jun 5, 2020 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 1, 2020 08:00AM UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 05:00PM Option Care Health Selected as Preferred Pharmacy Partner To Prepare and Distribute Breakthrough Cancer Therapy
May 15, 2020 09:04AM UroGen Pharma (URGN) Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
May 15, 2020 09:01AM UroGen Pharma (URGN) Reports Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto in Patients with Low-Grade Upper Tract Urothelial Cancer
May 15, 2020 09:01AM UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
May 15, 2020 09:00AM UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer
May 7, 2020 08:00AM UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments
May 1, 2020 08:00AM UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020
Apr 30, 2020 08:00AM The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
Apr 15, 2020 06:22PM UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
Apr 3, 2020 08:01AM UroGen Pharma (URGN) Reports Positive Interim Data from Phase 2b Study of UGN-102
Apr 3, 2020 08:00AM UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
Mar 23, 2020 08:00AM UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
Mar 6, 2020 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 2, 2020 08:00AM UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments
Feb 25, 2020 08:00AM UroGen Pharma Announces March 2020 Investor Conference Schedule
Feb 24, 2020 08:00AM UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020
Jan 8, 2020 08:00AM UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference
Dec 19, 2019 08:02AM UroGen Pharma (URGN) Announces FDA Filing Acceptance and Priority Review of U.S. NDA for UGN-101
Dec 19, 2019 08:00AM UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101
Jun 7, 2017 10:00AM UroGen Pharma Ltd. (Nasdaq: URGN), to Ring The Nasdaq Stock Market Opening Bell
View More Recent Stories